These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16464274)

  • 1. Clinical illness as a marker for initiation of HIV antiretroviral therapy in a rural setting, Rakai, Uganda.
    Spacek LA; Gray RH; Wawer MJ; Sewankambo NK; Serwadda D; Wabwire-Mangen F; Kiwanuka N; Kigozi G; Nalugoda F; Quinn TC;
    Int J STD AIDS; 2006 Feb; 17(2):116-20. PubMed ID: 16464274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda.
    Liechty CA; Solberg P; Were W; Ekwaru JP; Ransom RL; Weidle PJ; Downing R; Coutinho A; Mermin J
    Trop Med Int Health; 2007 Aug; 12(8):929-35. PubMed ID: 17697087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    Tam LW; Hogg RS; Yip B; Montaner JS; Harrigan PR; Brumme CJ
    HIV Med; 2007 Jul; 8(5):267-70. PubMed ID: 17561871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
    Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD;
    AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening HIV-positive pregnant women for antiretroviral therapy: utility of self-reported symptoms.
    Nguyen RH; Gange SJ; Serwadda D; Kigozi G; Kiwanuka N; Sewankambo NK; Wabwire-Mangen F; Quinn TC; Wawer M; Gray RH
    Int J STD AIDS; 2006 Feb; 17(2):112-5. PubMed ID: 16464273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and determinants of mortality and morbidity following early antiretroviral therapy initiation in HIV-infected adults in West Africa.
    Moh R; Danel C; Messou E; Ouassa T; Gabillard D; Anzian A; Abo Y; Salamon R; Bissagnene E; Seyler C; Eholié S; Anglaret X
    AIDS; 2007 Nov; 21(18):2483-91. PubMed ID: 18025885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral lesions as clinical markers of highly active antiretroviral therapy failure: a nested case-control study in Mexico City.
    Ramírez-Amador V; Ponce-de-León S; Anaya-Saavedra G; Crabtree Ramírez B; Sierra-Madero J
    Clin Infect Dis; 2007 Oct; 45(7):925-32. PubMed ID: 17806063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy.
    Weiser B; Philpott S; Klimkait T; Burger H; Kitchen C; Bürgisser P; Gorgievski M; Perrin L; Piffaretti JC; Ledergerber B;
    AIDS; 2008 Feb; 22(4):469-79. PubMed ID: 18301059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced fertility among HIV-infected women associated with viral load in Rakai district, Uganda.
    Nguyen RH; Gange SJ; Wabwire-Mangen F; Sewankambo NK; Serwadda D; Wawer MJ; Quinn TC; Gray RH
    Int J STD AIDS; 2006 Dec; 17(12):842-6. PubMed ID: 17212863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.
    Holkmann Olsen C; Mocroft A; Kirk O; Vella S; Blaxhult A; Clumeck N; Fisher M; Katlama C; Phillips AN; Lundgren JD;
    HIV Med; 2007 Mar; 8(2):96-104. PubMed ID: 17352766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.
    Srasuebkul P; Ungsedhapand C; Ruxrungtham K; Boyd MA; Phanuphak P; Cooper DA; Law MG
    HIV Med; 2007 Jan; 8(1):46-54. PubMed ID: 17305932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do HIV care providers appropriately manage hepatitis B in coinfected patients treated with antiretroviral therapy?
    Jain MK; Opio CK; Osuagwu CC; Pillai R; Keiser P; Lee WM
    Clin Infect Dis; 2007 Apr; 44(7):996-1000. PubMed ID: 17342656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent low-level viraemia and virological failure in HIV-1-infected patients treated with highly active antiretroviral therapy.
    Sungkanuparph S; Groger RK; Overton ET; Fraser VJ; Powderly WG
    HIV Med; 2006 Oct; 7(7):437-41. PubMed ID: 16925729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women.
    Lavreys L; Baeten JM; Chohan V; McClelland RS; Hassan WM; Richardson BA; Mandaliya K; Ndinya-Achola JO; Overbaugh J
    Clin Infect Dis; 2006 May; 42(9):1333-9. PubMed ID: 16586394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of depressive symptoms at ART initiation on HIV clinical progression and mortality: implications in clinical practice.
    Villes V; Spire B; Lewden C; Perronne C; Besnier JM; Garré M; Chêne G; Leport C; Carrieri MP; Le Moings V;
    Antivir Ther; 2007; 12(7):1067-74. PubMed ID: 18018765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.